Volume : 10, Issue : 01, January – 2023
03.REGULATORY GUIDELINES FOR CONDUCTING BIOAVAILABILITY AS PER USFDA
CH. Pallavi* and V. Saikishore
Bioavailability studies are critical studies used to support INDs and NDAs. BA refers to the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. This data is used to determine the fraction of drug absorbed and a drugs pharmacokinetics. FDA’s guidance focuses on the use of pharmacokinetic studies to document bioavailability data. Specifically, FDA provides recommendations on type of study, population composition, dosing, analytical methods, measures of systemic exposure, and other approaches to support bioavailability. To deliver many drugs to their site(s) of action, we rely on the systemic blood circulation, as opposed to locally acting drug products, such as ointments intended to treat a skin condition. For drug products intended for systemic absorption, bioavailability of a drug from its dosage form is generally determined by comparing its pharmacokinetic profile in blood with that after intravascular administration of the same drug in solution. The present study was aimed to study the need for bioavailability studies, ethical guidelines, experimental designs, pharmacokinetic endpoints, and their statistical evaluations. Specifically, the guidance addresses study design considerations, including in-vivo and in-vitro studies, and assessing BA for various dosage forms. Appendices provide recommendations for approaches for general study design and data handling, guidelines for conducting fed or fasted studies, and guidelines for conducting an in-vitro alcohol dose-dumping study.
Cite This Article:
Please cite this article in press CH. Pallavi et al, Regulatory Guidelines For Conducting Bioavailability As Per USFDA”., Indo Am. J. P. Sci, 2023; 10(01).
Number of Downloads : 10
1. Kaushal N, Singh SK, Gulati M, Vaidya Y, Kaushik M. Study of regulatory requirements for the conduct of bioequivalence studies in US, Europe, Canada, India, ASEAN and SADC countries: Impact on generic drug substitution. J App Pharm Sci, 2016; 6 (04): 206-222
2. Shaik M, Thirunagari BL, Sathe A. The basic regulatory considerations and prospects for conducting bioavailability/bioequivalence (BA/BE) studies- An overview. Comparative Effectiveness Research 2011; 1: 1-25.
3. Elkoshi Z, Behr D, Mirimsky A, Tsvetkov I, Danon A. Multiple dose studies can be a more sensitive assessment for bioequivalence than single dose studies: The cases with omeprazole. Clin Drug Investig, 2002; 22: 585-592
4. Rita B, Akhilesh T. Importance of Bioequivalence Studies for Enhancing Pharmacokinetic Parameters. Res. Rev.: J Pharm Nanotech, 2015; 3: 89-96.
5. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville, Maryland 20857, August 2000
6. USA. FDA, Guidance for Industry. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classication System [Internet]. December 2017 [cited 2021 Mar 23]. Available from: https://www.fda.gov/media/70963/download
7. Guidance for Industry, Handling and Retention of BA and BE Testing Samples, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), May 2004.
8. Guidance for Industry Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA, Draft Guidance, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Biopharmaceutics
9. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), BP, Revision 1, March 2003
10. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. 3. Chapman Hall/CRC Press, Taylor& Francis; New York, New York, USA: 2008.